409 related articles for article (PubMed ID: 27094971)
1. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
Wong LM; Tang V; Peters J; Costello A; Corcoran N
BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
[TBL] [Abstract][Full Text] [Related]
2. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
3. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
5. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
6. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
7. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
[TBL] [Abstract][Full Text] [Related]
9. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
10. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
[TBL] [Abstract][Full Text] [Related]
11. The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates.
Schiavina R; Borghesi M; Brunocilla E; Romagnoli D; Diazzi D; Giunchi F; Vagnoni V; Pultrone CV; Dababneh H; Porreca A; Fiorentino M; Martorana G
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):270-5. PubMed ID: 26055663
[TBL] [Abstract][Full Text] [Related]
12. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
14. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
15. Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy.
Berg KD; Røder MA; Brasso K; Vainer B; Iversen P
Scand J Urol; 2014 Apr; 48(2):168-76. PubMed ID: 23889119
[TBL] [Abstract][Full Text] [Related]
16. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
17. Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.
Norman Z; Militza P; Andres F; Daniela F; Alejandro M; Catherine S; Juan F
Int Braz J Urol; 2014; 40(2):154-9. PubMed ID: 24856482
[TBL] [Abstract][Full Text] [Related]
18. Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.
Tsang CF; Tsu JH; Lai TC; Wong KW; Ho BS; Ng AT; Ma WK; Yiu MK
Hong Kong Med J; 2017 Dec; 23(6):609-15. PubMed ID: 29026057
[TBL] [Abstract][Full Text] [Related]
19. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
